Nanocarrier strategies to overcome P-glycoprotein-mediated drug resistance in cancer therapy

• Andreina Quevedo-Enríquez,
• Katty Yi Zhang,
• Denisse Yajaira Enriquez,
• Byron Raul Inapanta,
• Roxana Noemí Peroni and
• Christian Rafael Quijia

Beilstein J. Nanotechnol. 2026, 17, 882–921, doi:10.3762/bjnano.17.64

• . Keywords: cancer chemotherapy; efflux transporters; multidrug resistance (MDR); nanoparticles; siRNA nanocarriers; tumor-targeted therapy; Review 1 Introduction 1.1 Cancer and current challenges in chemotherapy Cancer remains one of the leading causes of mortality worldwide, with millions of new cases

Synthetic-polymer-assisted antisense oligonucleotide delivery: targeted approaches for precision disease treatment

• Ana Cubillo Alvarez,
• Dylan Maguire and
• Ruairí P. Brannigan

Beilstein J. Nanotechnol. 2025, 16, 435–463, doi:10.3762/bjnano.16.34

• cytotoxicity and improved intracellular delivery of Bcl-2 siRNAs compared to PLL–siRNA and PEG-b-PLL–siRNA nanocarriers [145]. Nowadays, because of the straightforward synthesis and commercial availability, PAMAM dendrimers are considered the main dendritic system for nucleic acid delivery and gene transfer

Brome mosaic virus-like particles as siRNA nanocarriers for biomedical purposes

• Alfredo Nuñez-Rivera,
• Pierrick G. J. Fournier,
• Danna L. Arellano,
• Ana G. Rodriguez-Hernandez,
• Rafael Vazquez-Duhalt and
• Ruben D. Cadena-Nava

Beilstein J. Nanotechnol. 2020, 11, 372–382, doi:10.3762/bjnano.11.28